|
Advisory
Committees
Waivers for Conflicts of Interest
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.
Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007. This provision was repealed, effective October 1, 2007, by the FDA.
Oncologic Drugs Advisory Committee
December 16, 2008
Jean Grem, M.D.
• 18 U.S.C. 208 waiver (pdf)
• Acknowledgement and Consent (pdf)
David Harrington, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
• Acknowledgement and Consent (pdf)
Derek Raghavan, M.D.
• 18 U.S.C. 208 waiver (pdf)
• Acknowledgement and Consent (pdf)
Page updated:
December 1, 2008
|
|